Characterisation and induction of tissue-resident gamma delta T-cells to target hepatocellular carcinoma.
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
16 03 2022
16 03 2022
Historique:
received:
29
05
2021
accepted:
17
02
2022
entrez:
17
3
2022
pubmed:
18
3
2022
medline:
6
4
2022
Statut:
epublish
Résumé
Immunotherapy is now the standard of care for advanced hepatocellular carcinoma (HCC), yet many patients fail to respond. A major unmet goal is the boosting of T-cells with both strong HCC reactivity and the protective advantages of tissue-resident memory T-cells (T
Identifiants
pubmed: 35296658
doi: 10.1038/s41467-022-29012-1
pii: 10.1038/s41467-022-29012-1
pmc: PMC8927126
doi:
Substances chimiques
Receptors, Antigen, T-Cell, gamma-delta
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1372Subventions
Organisme : Wellcome Trust
ID : 175479
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 214191/Z/18/Z
Pays : United Kingdom
Organisme : Cancer Research UK
ID : 26813
Pays : United Kingdom
Organisme : Department of Health
Pays : United Kingdom
Organisme : Cancer Research UK
ID : 26603
Pays : United Kingdom
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : MRF
ID : MRF_MRF-044-0001-RG-SWADL
Pays : United Kingdom
Informations de copyright
© 2022. The Author(s).
Références
Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality Worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209–249 (2021).
pubmed: 33538338
doi: 10.3322/caac.21660
Pinato, D. J. et al. Immune-based therapies for hepatocellular carcinoma. Oncogene 39, 3620–3637 (2020).
pubmed: 32157213
pmcid: 7190571
doi: 10.1038/s41388-020-1249-9
Finn, R. S. et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N. Engl. J. Med 382, 1894–1905 (2020).
pubmed: 32402160
doi: 10.1056/NEJMoa1915745
Llovet, J. M. et al. Hepatocellular carcinoma. Nat. Rev. Dis. Prim. 7, 6 (2021).
pubmed: 33479224
doi: 10.1038/s41572-020-00240-3
Prieto, J., Melero, I. & Sangro, B. Immunological landscape and immunotherapy of hepatocellular carcinoma. Nat. Rev. Gastroenterol. Hepatol. 12, 681–700 (2015).
pubmed: 26484443
doi: 10.1038/nrgastro.2015.173
Gubin, M. M. et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 515, 577–581 (2014).
pubmed: 25428507
pmcid: 4279952
doi: 10.1038/nature13988
Lindblad, K. E., Ruiz de Galarreta, M. & Lujambio, A. Tumor-intrinsic mechanisms regulating immune exclusion in liver cancers. Frontiers in Immunology 12, 720 (2021).
Ruf, B., Heinrich, B. & Greten, T. F. Immunobiology and immunotherapy of HCC: spotlight on innate and innate-like immune cells. Cell. Mol. Immunol. 18, 112–127 (2021).
pubmed: 33235387
doi: 10.1038/s41423-020-00572-w
Gentles, A. J. et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat. Med 21, 938–945 (2015).
pubmed: 26193342
pmcid: 4852857
doi: 10.1038/nm.3909
Tosolini, M. et al. Assessment of tumor-infiltrating TCRVγ9Vδ2 γδ lymphocyte abundance by deconvolution of human cancers microarrays. Oncoimmunology 6, e1284723 (2017).
pubmed: 28405516
pmcid: 5384348
doi: 10.1080/2162402X.2017.1284723
Wu, Y. et al. An innate-like Vδ1(+) γδ T cell compartment in the human breast is associated with remission in triple-negative breast cancer. Sci Transl Med 11, eaax9364 (2019).
Meraviglia, S. et al. Distinctive features of tumor-infiltrating γδ T lymphocytes in human colorectal cancer. Oncoimmunology 6, e1347742 (2017).
pubmed: 29123962
pmcid: 5665062
doi: 10.1080/2162402X.2017.1347742
Wang, J. et al. Tumor-infiltrating γδT cells predict prognosis and adjuvant chemotherapeutic benefit in patients with gastric cancer. Oncoimmunology 6, e1353858 (2017).
pubmed: 29147601
pmcid: 5674957
doi: 10.1080/2162402X.2017.1353858
Girardi, M. et al. Regulation of cutaneous malignancy by gammadelta T cells. Science 294, 605–609 (2001).
pubmed: 11567106
doi: 10.1126/science.1063916
Girardi, M. et al. The distinct contributions of murine T cell receptor (TCR)gammadelta+ and TCRalphabeta+ T cells to different stages of chemically induced skin cancer. J. Exp. Med 198, 747–755 (2003).
pubmed: 12953094
pmcid: 2194182
doi: 10.1084/jem.20021282
Liu, Z. et al. Protective immunosurveillance and therapeutic antitumor activity of gammadelta T cells demonstrated in a mouse model of prostate cancer. J. Immunol. 180, 6044–6053 (2008).
pubmed: 18424725
doi: 10.4049/jimmunol.180.9.6044
Vantourout, P. & Hayday, A. Six-of-the-best: unique contributions of γδ T cells to immunology. Nat. Rev. Immunol. 13, 88–100 (2013).
pubmed: 23348415
pmcid: 3951794
doi: 10.1038/nri3384
Kabelitz, D., Serrano, R., Kouakanou, L., Peters, C. & Kalyan, S. Cancer immunotherapy with γδ T cells: many paths ahead of us. Cell. Mol.Immunol. 17, 925–939 (2020).
pubmed: 32699351
pmcid: 7609273
doi: 10.1038/s41423-020-0504-x
Groh, V. et al. Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB. Proc. Natl Acad. Sci. 96, 6879–6884 (1999).
pubmed: 10359807
pmcid: 22010
doi: 10.1073/pnas.96.12.6879
Hayday, A. C. & Vantourout, P. The innate biologies of adaptive antigen receptors. Annu Rev. Immunol. 38, 487–510 (2020).
pubmed: 32017636
doi: 10.1146/annurev-immunol-102819-023144
Rigau, M. et al. Butyrophilin 2A1 is essential for phosphoantigen reactivity by γδ T cells. Science 367, eaay5516 (2020).
pubmed: 31919129
doi: 10.1126/science.aay5516
Nussbaumer, O. & Koslowski, M. The emerging role of γδ T cells in cancer immunotherapy. Immuno-Oncol. Technol. 1, 3–10 (2019).
doi: 10.1016/j.iotech.2019.06.002
Fisher, J. P., Heuijerjans, J., Yan, M., Gustafsson, K. & Anderson, J. γδ T cells for cancer immunotherapy: A systematic review of clinical trials. Oncoimmunology 3, e27572 (2014).
pubmed: 24734216
pmcid: 3984269
doi: 10.4161/onci.27572
Hoeres, T., Smetak, M., Pretscher, D. & Wilhelm, M. Improving the efficiency of Vγ9Vδ2 T-cell immunotherapy in cancer. Front Immunol. 9, 800 (2018).
pubmed: 29725332
pmcid: 5916964
doi: 10.3389/fimmu.2018.00800
Park, S. L., Gebhardt, T. & Mackay, L. K. Tissue-resident memory T cells in cancer immunosurveillance. Trends Immunol. 40, 735–747 (2019).
pubmed: 31255505
doi: 10.1016/j.it.2019.06.002
Okła, K., Farber, D. L. & Zou, W. Tissue-resident memory T cells in tumor immunity and immunotherapy. J Exp Med 218, 1–14 (2021).
Amsen, D., van Gisbergen, K., Hombrink, P. & van Lier, R. A. W. Tissue-resident memory T cells at the center of immunity to solid tumors. Nat. Immunol. 19, 538–546 (2018).
pubmed: 29777219
doi: 10.1038/s41590-018-0114-2
Pallett, L. J. et al. IL-2(high) tissue-resident T cells in the human liver: Sentinels for hepatotropic infection. J. Exp. Med 214, 1567–1580 (2017).
pubmed: 28526759
pmcid: 5461007
doi: 10.1084/jem.20162115
Stelma, F. et al. Human intrahepatic CD69 + CD8+ T cells have a tissue resident memory T cell phenotype with reduced cytolytic capacity. Sci. Rep. 7, 6172 (2017).
pubmed: 28733665
pmcid: 5522381
doi: 10.1038/s41598-017-06352-3
Pallett, L. J. et al. Longevity and replenishment of human liver-resident memory T cells and mononuclear phagocytes. J Exp Med 217, 1–11 (2020).
Egelston, C. A. et al. Resident memory CD8+ T cells within cancer islands mediate survival in breast cancer patients. JCI Insight 4, 1–15 (2019).
Byrne, A. et al. Tissue-resident memory T cells in breast cancer control and immunotherapy responses. Nat. Rev. Clin. Oncol. 17, 341–348 (2020).
pubmed: 32112054
doi: 10.1038/s41571-020-0333-y
Park, S. L. et al. Tissue-resident memory CD8(+) T cells promote melanoma-immune equilibrium in skin. Nature 565, 366–371 (2019).
pubmed: 30598548
doi: 10.1038/s41586-018-0812-9
Lim, C. J. et al. Multidimensional analyses reveal distinct immune microenvironment in hepatitis B virus-related hepatocellular carcinoma. Gut 68, 916–927 (2019).
pubmed: 29970455
doi: 10.1136/gutjnl-2018-316510
Clarke, J. et al. Single-cell transcriptomic analysis of tissue-resident memory T cells in human lung cancer. J. Exp. Med 216, 2128–2149 (2019).
pubmed: 31227543
pmcid: 6719422
doi: 10.1084/jem.20190249
Ganesan, A. P. et al. Tissue-resident memory features are linked to the magnitude of cytotoxic T cell responses in human lung cancer. Nat. Immunol. 18, 940–950 (2017).
pubmed: 28628092
pmcid: 6036910
doi: 10.1038/ni.3775
Malik, B. T. et al. Resident memory T cells in the skin mediate durable immunity to melanoma. Sci Immunol 2, 1–24 (2017).
Menares, E. et al. Tissue-resident memory CD8+ T cells amplify anti-tumor immunity by triggering antigen spreading through dendritic cells. Nat. Commun. 10, 4401 (2019).
pubmed: 31562311
pmcid: 6765014
doi: 10.1038/s41467-019-12319-x
Savas, P. et al. Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis. Nat. Med. 24, 986–993 (2018).
pubmed: 29942092
doi: 10.1038/s41591-018-0078-7
Cheng, Y. et al. Non-terminally exhausted tumor-resident memory HBV-specific T cell responses correlate with relapse-free survival in hepatocellular carcinoma. Immunity 54, 1825–1840 (2021).
pubmed: 34270940
doi: 10.1016/j.immuni.2021.06.013
Hunter, S. et al. Human liver infiltrating gammadelta T cells are composed of clonally expanded circulating and tissue-resident populations. J. Hepatol. 69, 654–665 (2018).
pubmed: 29758330
pmcid: 6089840
doi: 10.1016/j.jhep.2018.05.007
Davey, M. S. et al. The human Vδ2(+) T-cell compartment comprises distinct innate-like Vγ9(+) and adaptive Vγ9(-) subsets. Nat. Commun. 9, 1760 (2018).
pubmed: 29720665
pmcid: 5932074
doi: 10.1038/s41467-018-04076-0
Heydtmann, M. et al. CXC chemokine ligand 16 promotes integrin-mediated adhesion of liver-infiltrating lymphocytes to cholangiocytes and hepatocytes within the inflamed human liver. J. Immunol. 174, 1055–1062 (2005).
pubmed: 15634930
doi: 10.4049/jimmunol.174.2.1055
Curbishley, S. M., Eksteen, B., Gladue, R. P., Lalor, P. & Adams, D. H. CXCR 3 activation promotes lymphocyte transendothelial migration across human hepatic endothelium under fluid flow. Am. J. Pathol. 167, 887–899 (2005).
pubmed: 16127166
pmcid: 1698725
doi: 10.1016/S0002-9440(10)62060-3
Fernandez-Ruiz, D. et al. Liver-resident memory CD8(+) T cells form a front-line defense against malaria liver-stage infection. Immunity 45, 889–902 (2016).
pubmed: 27692609
doi: 10.1016/j.immuni.2016.08.011
Behr, F. M. et al. Blimp-1 rather than hobit drives the formation of tissue-resident memory CD8+ T cells in the lungs. Frontiers in Immunology 10, 1–14 (2019).
Zhou, X. et al. Differentiation and persistence of memory CD8+ T cells depend on T cell factor 1. Immunity 33, 229–240 (2010).
pubmed: 20727791
pmcid: 2928475
doi: 10.1016/j.immuni.2010.08.002
Tang, Z., Kang, B., Li, C., Chen, T. & Zhang, Z. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res. 47, W556–W560 (2019).
pubmed: 31114875
pmcid: 6602440
doi: 10.1093/nar/gkz430
Pizzolato, G. et al. Single-cell RNA sequencing unveils the shared and the distinct cytotoxic hallmarks of human TCRVδ1 and TCRVδ2 γδ T lymphocytes. Proc. Natl Acad. Sci. 116, 11906–11915 (2019).
pubmed: 31118283
pmcid: 6576116
doi: 10.1073/pnas.1818488116
Rha, M. S., et al. Impaired antibacterial response of liver sinusoidal Vγ9(+)Vδ2(+) T cells in patients with chronic liver disease. Gut 71, 605–615 (2021).
Sugai, S. et al. Hepatocellular carcinoma cell sensitivity to Vγ9Vδ2 T lymphocyte-mediated killing is increased by zoledronate. Int J. Oncol. 48, 1794–1804 (2016).
pubmed: 26936487
pmcid: 4809658
doi: 10.3892/ijo.2016.3403
Benzaïd, I. et al. High phosphoantigen levels in bisphosphonate-treated human breast tumors promote Vgamma9Vdelta2 T-cell chemotaxis and cytotoxicity in vivo. Cancer Res 71, 4562–4572 (2011).
pubmed: 21646473
doi: 10.1158/0008-5472.CAN-10-3862
Cimini, E. et al. Zoledronic acid enhances Vδ2 T-lymphocyte antitumor response to human glioma cell lines. Int J. Immunopathol. Pharm. 24, 139–148 (2011).
doi: 10.1177/039463201102400116
Gober, H. J. et al. Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells. J. Exp. Med 197, 163–168 (2003).
pubmed: 12538656
pmcid: 2193814
doi: 10.1084/jem.20021500
Kondo, M. et al. Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy. Cytotherapy 10, 842–856 (2008).
pubmed: 19016372
doi: 10.1080/14653240802419328
Kakimi, K. et al. Adoptive transfer of zoledronate-expanded autologous Vγ9Vδ2 T-cells in patients with treatment-refractory non-small-cell lung cancer: a multicenter, open-label, single-arm, phase 2 study. J Immunother Cancer 8, 1–13 (2020).
Wada, I. et al. Intraperitoneal injection of in vitro expanded Vγ9Vδ2 T cells together with zoledronate for the treatment of malignant ascites due to gastric cancer. Cancer Med 3, 362–375 (2014).
pubmed: 24515916
pmcid: 3987085
doi: 10.1002/cam4.196
Sakamoto, M. et al. Adoptive immunotherapy for advanced non-small cell lung cancer using zoledronate-expanded γδTcells: a phase I clinical study. J. Immunother. 34, 202–211 (2011).
pubmed: 21304399
doi: 10.1097/CJI.0b013e318207ecfb
Dieli, F. et al. Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. Cancer Res 67, 7450–7457 (2007).
pubmed: 17671215
pmcid: 3915341
doi: 10.1158/0008-5472.CAN-07-0199
Wang, H. et al. Indirect stimulation of human Vγ2Vδ2 T cells through alterations in isoprenoid metabolism. J. Immunol. 187, 5099–5113 (2011).
pubmed: 22013129
doi: 10.4049/jimmunol.1002697
Castella, B. et al. Immune modulation by zoledronic acid in human myeloma: an advantageous cross-talk between Vγ9Vδ2 T cells, αβ CD8+ T cells, regulatory T cells, and dendritic cells. J. Immunol. 187, 1578–1590 (2011).
pubmed: 21753152
doi: 10.4049/jimmunol.1002514
Castella, B. et al. The ATP-binding cassette transporter A1 regulates phosphoantigen release and Vγ9Vδ2 T cell activation by dendritic cells. Nat. Commun. 8, 15663 (2017).
pubmed: 28580927
pmcid: 5465356
doi: 10.1038/ncomms15663
Roelofs, A. J. et al. Peripheral blood monocytes are responsible for gammadelta T cell activation induced by zoledronic acid through accumulation of IPP/DMAPP. Br. J. Haematol. 144, 245–250 (2009).
pubmed: 19016713
pmcid: 2659391
doi: 10.1111/j.1365-2141.2008.07435.x
Richter, M. V. & Topham, D. J. The α1β1 integrin and TNF receptor II protect airway CD8+ effector T cells from apoptosis during influenza infection. J. Immunol. 179, 5054–5063 (2007).
pubmed: 17911590
doi: 10.4049/jimmunol.179.8.5054
Yi, Y. et al. The functional impairment of HCC-infiltrating gammadelta T cells, partially mediated by regulatory T cells in a TGFbeta- and IL-10-dependent manner. J. Hepatol. 58, 977–983 (2013).
pubmed: 23262246
doi: 10.1016/j.jhep.2012.12.015
Zhao, Y., Niu, C. & Cui, J. Gamma-delta (γδ) T cells: friend or foe in cancer development? J. Transl. Med 16, 3 (2018).
pubmed: 29316940
pmcid: 5761189
doi: 10.1186/s12967-017-1378-2
Ma, S. et al. IL-17A produced by γδ T cells promotes tumor growth in hepatocellular carcinoma. Cancer Res. 74, 1969 (2014).
pubmed: 24525743
doi: 10.1158/0008-5472.CAN-13-2534
Gao, Y. et al. Gamma delta T cells provide an early source of interferon gamma in tumor immunity. J. Exp. Med 198, 433–442 (2003).
pubmed: 12900519
pmcid: 2194096
doi: 10.1084/jem.20030584
Xu, Y. et al. Allogeneic Vγ9Vδ2 T-cell immunotherapy exhibits promising clinical safety and prolongs the survival of patients with late-stage lung or liver cancer. Cell. Mol. Immunol. 18, 427–439 (2021).
pubmed: 32939032
doi: 10.1038/s41423-020-0515-7
Russell, R. G. Bisphosphonates: the first 40 years. Bone 49, 2–19 (2011).
pubmed: 21555003
doi: 10.1016/j.bone.2011.04.022
Kobayashi, H., Tanaka, Y., Yagi, J., Minato, N. & Tanabe, K. Phase I/II study of adoptive transfer of γδ T cells in combination with zoledronic acid and IL-2 to patients with advanced renal cell carcinoma. Cancer Immunol. Immunother. 60, 1075–1084 (2011).
pubmed: 21519826
doi: 10.1007/s00262-011-1021-7
Lang, J. M. et al. Pilot trial of interleukin-2 and zoledronic acid to augment γδ T cells as treatment for patients with refractory renal cell carcinoma. Cancer Immunol., Immunother. 60, 1447–1460 (2011).
doi: 10.1007/s00262-011-1049-8
Meraviglia, S. et al. In vivo manipulation of V9V2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients. Clin. Exp. Immunol. 161, 290–297 (2010).
pubmed: 20491785
pmcid: 2909411
doi: 10.1111/j.1365-2249.2010.04167.x
Jarry, U. et al. Stereotaxic administrations of allogeneic human Vγ9Vδ2 T cells efficiently control the development of human glioblastoma brain tumors. Oncoimmunology 5, e1168554 (2016).
pubmed: 27471644
pmcid: 4938356
doi: 10.1080/2162402X.2016.1168554